A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.

A Double-Blind, Randomized, Placebo Controlled Study of An Oral Antihistamine on Local Injection Site Reactions Among Persons With Multiple Sclerosis Who Perform Daily Injections of Copaxone® Using Autoject® 2 for Glass Syringe.

This study is designed to compare injection skin (injection site) reactions when an antihistamine (Zyrtec®) or placebo is taken prior to performing daily Copaxone® injections. Patients will be assigned (like a flip of a coin) to take either a placebo or an antihistamine (Zyrtec®) prior to performing their daily Copaxone® injections. The patient and physician will be unaware whether they are taking a placebo or antihistamine during the study.

Inclusion Criteria:

• Male or female
• 18 years of age or older
• Diagnosis of RRMS
• Beginning or recently (within < 3months) began self-injecting Copaxone®

Exclusion Criteria:

• Taking any other immunomodulatory therapy in conjunction with Copaxone®
• Unable to perform subcutaneous self-injection
• Pregnant or trying to become pregnant, or breast feeding during the study
• Previously participated in this study or in another clinical trial in the past 30 days